← Syndax Pharmaceuticals Inc
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $1.2m |
$2.1m
+72.79%
|
$1.5m
-28.04%
|
$1.5m
0.00%
|
$1.5m
0.00%
|
$139.7m
+9109.56%
|
$0
-100.00%
|
$0 | $23.7m |
$172.4m
+627.84%
|
$252.3m
+46.36%
|
|
| Research and Development Expense | $31.7m | $48.2m | $60.1m | $43.0m | $50.4m | $88.2m | $118.5m | $163.0m | $241.6m | $258.8m | $261.8m | |
| General and Administrative Expense | $13.3m | $15.9m | $17.3m | $16.1m | $22.5m | $25.2m | $33.3m | $66.9m | $120.9m | $179.7m | $174.0m | |
| Operating Lease, Expense | — | — | — | $447k | $425k | $413k | $440k | $743k | $1.1m | $900k | — | |
| Operating Expenses | $45.0m | $64.1m | $77.4m | $59.1m | $72.9m | $113.5m | $151.8m | $230.0m | $363.4m | $445.4m | $446.4m | |
| Operating Income (Loss) | ($43.8m) |
($62.0m)
-41.56%
|
($75.9m)
-22.47%
|
($57.5m)
+24.17%
|
($71.4m)
-24.13%
|
$26.2m
+136.71%
|
($151.8m)
-678.78%
|
($230.0m)
-51.53%
|
($339.7m)
-47.71%
|
($273.1m)
+19.60%
|
($194.2m)
+28.90%
|
|
| Interest Expense | $956k | $1.4m | $1.9m | $1.6m | $2.4m | $1.9m | $3.1m | $208k | $4.9m | $6k | $42.4m | |
| Other Nonoperating Income (Expense) | $41k | ($269k) | ($27k) | ($79k) | ($219k) | $202k | ($316k) | ($361k) | ($247k) | ($1.3m) | — | |
| Interest Expense (non-operating) | — | — | — | — | — | — | — | — | $4.9m | $6k | $42.4m | |
| Interest Income (Expense), Nonoperating, Net | $956k | $1.4m | $1.9m | $1.6m | $2.4m | $1.9m | $3.1m | $208k | $4.9m | $6k | $16.9m | |
| Income Tax Expense (Benefit) | $0 | $0 | $0 | $0 | $0 | $0 | — | — | — | $433k | — | |
| Net Income (Loss) Attributable to Parent | ($44.5m) |
($60.8m)
-36.72%
|
($74.0m)
-21.64%
|
($56.0m)
+24.22%
|
($73.2m)
-30.53%
|
$24.9m
+134.07%
|
($149.3m)
-699.13%
|
($209.4m)
-40.19%
|
($318.8m)
-52.25%
|
($285.4m)
+10.46%
|
($220.8m)
+22.65%
|
|
| Net Income (Loss) Available to Common Stockholders, Basic | ($47.1m) |
($60.8m)
-29.17%
|
($74.0m)
-21.64%
|
($56.0m)
+24.22%
|
($77.1m)
-37.50%
|
$24.9m
+132.34%
|
($149.3m)
-699.13%
|
($209.4m)
-40.19%
|
($318.8m)
-52.25%
|
($285.4m)
+10.46%
|
($220.8m)
+22.65%
|
|
| Earnings Per Share, Basic | — | — | — | ($1.84) | ($1.87) | $0.48 | ($2.46) | ($2.98) | ($3.72) | ($3.29) | ($2.51) | |
| Earnings Per Share, Diluted | ($3.22) | ($2.90) | ($2.92) | ($1.84) | ($1.87) | $0.46 | ($2.46) | ($2.98) | ($3.72) | ($3.29) | ($2.51) | |
| Weighted Average Number of Shares Outstanding, Basic | — | — | — | — | — | 52.1m | 60.8m | 70.4m | 85.6m | 86.6m | 87.8m | |
| Weighted Average Number of Shares Outstanding, Diluted | — | — | — | — | — | 53.6m | 60.8m | 70.4m | 85.6m | 86.6m | 87.8m |